PT1984345E - Benzoxazinas e compostos heterobicíclicos contendo azoto relacionados, úteis como agentes de modulação do receptor de mineralocorticóides - Google Patents

Benzoxazinas e compostos heterobicíclicos contendo azoto relacionados, úteis como agentes de modulação do receptor de mineralocorticóides Download PDF

Info

Publication number
PT1984345E
PT1984345E PT07713915T PT07713915T PT1984345E PT 1984345 E PT1984345 E PT 1984345E PT 07713915 T PT07713915 T PT 07713915T PT 07713915 T PT07713915 T PT 07713915T PT 1984345 E PT1984345 E PT 1984345E
Authority
PT
Portugal
Prior art keywords
benzoxazines
compounds useful
modulating agents
mineralocorticoid receptor
receptor modulating
Prior art date
Application number
PT07713915T
Other languages
English (en)
Inventor
Toru Iijima
Yasuo Yamamoto
Hidenori Akatsuka
Takayuki Kawaguchi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of PT1984345E publication Critical patent/PT1984345E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/161,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
PT07713915T 2006-02-02 2007-02-01 Benzoxazinas e compostos heterobicíclicos contendo azoto relacionados, úteis como agentes de modulação do receptor de mineralocorticóides PT1984345E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006025403 2006-02-02
JP2006275917 2006-10-10

Publications (1)

Publication Number Publication Date
PT1984345E true PT1984345E (pt) 2011-09-08

Family

ID=38110055

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07713915T PT1984345E (pt) 2006-02-02 2007-02-01 Benzoxazinas e compostos heterobicíclicos contendo azoto relacionados, úteis como agentes de modulação do receptor de mineralocorticóides

Country Status (16)

Country Link
US (2) US7998956B2 (pt)
EP (1) EP1984345B9 (pt)
KR (1) KR101046548B1 (pt)
AR (1) AR059280A1 (pt)
AT (1) ATE522511T1 (pt)
AU (1) AU2007210424C1 (pt)
BR (1) BRPI0707491B8 (pt)
CA (1) CA2636985C (pt)
DK (1) DK1984345T3 (pt)
MX (1) MX285869B (pt)
PH (1) PH12008501738B1 (pt)
PL (1) PL1984345T3 (pt)
PT (1) PT1984345E (pt)
RU (1) RU2398769C2 (pt)
TW (1) TWI385161B (pt)
WO (1) WO2007089034A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622231B (zh) * 2007-02-28 2013-12-04 艾德维纳斯医疗私人有限公司 作为葡糖激酶激活剂的2,2,2-三取代的乙酰胺衍生物、它们的制造方法和药学应用
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
EP2266989B1 (en) * 2008-03-31 2015-09-02 C&c Research Laboratories Heterocyclic derivatives
CA2719376A1 (en) * 2008-04-07 2009-10-15 Gilead Sciences, Inc. 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors
IN2014CN04174A (pt) 2011-12-22 2015-09-04 Novartis Ag
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
CN104507919B (zh) 2012-08-08 2016-05-25 田边三菱制药株式会社 1,4-苯并噁嗪化合物的制造方法
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
WO2015074064A2 (en) 2013-11-18 2015-05-21 Bair Kenneth W Tetrahydroquinoline compositions as bet bromodomain inhibitors
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
CN103694137A (zh) * 2013-12-06 2014-04-02 常州工程职业技术学院 一种2-氟-4-硝基苯甲腈的清洁生产方法
EA029518B1 (ru) 2014-06-30 2018-04-30 Астразенека Аб Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
TWI603962B (zh) 2016-09-10 2017-11-01 國立清華大學 含硫噁嗪化合物及其合成方法
MX2019003470A (es) 2016-09-27 2019-08-29 Mitsubishi Tanabe Pharma Corp Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
US10918639B2 (en) 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2018149754A1 (en) 2017-02-16 2018-08-23 Basf Se Pyridine compounds
WO2018153898A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
DE102017008472A1 (de) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
TW202045184A (zh) 2019-02-05 2020-12-16 日商田邊三菱製藥股份有限公司 預防或治療肺纖維化的藥物
JPWO2021107029A1 (pt) 2019-11-26 2021-06-03
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224941B (pt) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
US5420126A (en) 1989-11-08 1995-05-30 Yamanouchi Pharmaceutical Co., Ltd. 3,4-dihydro-2H-1,4-benzoxazine derivatives and pharmaceutical compositions containing the same
CN1029479C (zh) 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5696117A (en) 1995-11-07 1997-12-09 Ortho Pharmaceutical Corporation Benzoxazine antimicrobial agents
DE19727117A1 (de) 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6498154B1 (en) * 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
EP1255743A1 (en) * 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
BRPI0406883A (pt) * 2003-01-22 2006-01-03 Lilly Co Eli Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
ES2308296T3 (es) 2003-12-19 2008-12-01 Eli Lilly And Company Modulares del receptor nuclear de hormonas esteroideas triciclicas.
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
EP1844768A1 (en) * 2005-01-19 2007-10-17 Dainippon Sumitomo Pharma Co., Ltd. Aromatic sulfone compound as aldosterone receptor modulator

Also Published As

Publication number Publication date
BRPI0707491B8 (pt) 2021-05-25
AU2007210424B2 (en) 2010-07-15
US20090023716A1 (en) 2009-01-22
RU2398769C2 (ru) 2010-09-10
TWI385161B (zh) 2013-02-11
PH12008501738B1 (en) 2013-11-29
EP1984345B1 (en) 2011-08-31
CA2636985A1 (en) 2007-08-09
US8188073B2 (en) 2012-05-29
US20110251185A1 (en) 2011-10-13
CA2636985C (en) 2011-08-16
AU2007210424A1 (en) 2007-08-09
AU2007210424C1 (en) 2010-11-18
WO2007089034A1 (en) 2007-08-09
EP1984345B9 (en) 2012-03-21
BRPI0707491B1 (pt) 2019-12-10
RU2008135468A (ru) 2010-03-10
KR101046548B1 (ko) 2011-07-05
PL1984345T3 (pl) 2012-01-31
TW200800926A (en) 2008-01-01
AR059280A1 (es) 2008-03-19
DK1984345T3 (da) 2011-12-12
US7998956B2 (en) 2011-08-16
ATE522511T1 (de) 2011-09-15
KR20080083698A (ko) 2008-09-18
BRPI0707491A2 (pt) 2011-05-03
MX285869B (en) 2011-04-19
EP1984345A1 (en) 2008-10-29

Similar Documents

Publication Publication Date Title
PH12008501738B1 (en) Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents
IL183665A0 (en) Heterocyclic compounds as ccr2b antagonists
IL193042A0 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as sip receptor agonists
HK1167397A1 (zh) 作為抗癌症劑的 -取代的喹唑酮衍生物
EP2155818A4 (en) COMPOSITIONS SUITABLE FOR USE AS GROUNDING COMPOUNDS AND ASSOCIATED METHODS
HK1147674A1 (en) Heterocyclic compounds as crth2 receptor antagonists crth2
IL198241A0 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
EP2188271A4 (en) HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
IL194815A0 (en) Fused heterocyclic compounds and their use as mglur5 modulators
IL195158A0 (en) Novel heterocyclic compounds
IL183647A0 (en) 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
EP1991200A4 (en) FLUORCHINOLONZUSAMMENSETZUNGEN
IL199971A0 (en) Heterocyclic derivatives as m3 muscarinic receptors
EP2025671A4 (en) NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
EP2065439A4 (en) polyolefin
EP2039695A4 (en) BICYCLIC HETEROCYLIC COMPOUND AND ITS USE
ZA200705159B (en) Heterocyclic compounds as CCR2B antagonists
IL189463A0 (en) Non-steroidal compounds useful as glucocorticoid receptor modulators
ZA200704979B (en) 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
GB0619308D0 (en) Heterocyclic compounds
IL173733A0 (en) Microbial compositions useful for the degradation of hydrocarbons
GB0624212D0 (en) Heterobicyclic, nitrogen-containing compounds
ZA200809385B (en) Novel heterocyclic compounds
RS56117B1 (sr) Derivati 5-supstituisanog hinazolinona kao antikancer agensi